

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) ~~Use of sulfated glycosaminoglycans~~  
~~having an anticoagulant activity of 100 BP units/mg or less for~~  
~~the manufacture of a pharmaceutical preparation~~ A method for  
prophylactic priming or curative treatment of the cervix and the  
myometrium for establishing effective labor in women, comprising  
the step of:

administering to a pregnant woman an effective amount of at  
least one sulfated glycosaminoglycan having an anticoagulant  
activity of 100 BP units/mg or less.

2. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method  
according to claim 1, ~~which belongs to~~ wherein the at least one  
glycosaminoglycan comprises at least one glycosaminoglycan  
selected from the group consisting of heparan sulfates sulfate  
and depolymerised heparan ~~sulfates~~ sulfate.

3. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method  
according to claim 1, ~~which belongs to~~ wherein the at least one  
glycosaminoglycan comprises at least one glycosaminoglycan  
selected from the group consisting of chondroitin sulfates  
sulfate and depolymerised chondroitin ~~sulfates~~ sulfate.

4. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to claim 1, ~~which belongs to~~ wherein the at least one glycosaminoglycan comprises at least one glycosaminoglycan selected from the group consisting of dermatan sulfates sulfate or and depolymerised dermatan sulfates sulfate.

5. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to claim 1, ~~which belongs to~~ wherein the at least one glycosaminoglycan comprises the group consisting of depolymerised heparins heparin having an average molecular weight below 10 000 Da, ~~preferably not higher than 6000 Da.~~

6. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to any one of claims 1-5, ~~having~~ wherein the at least one glycosaminoglycan has an anticoagulant activity of 30 BP units/mg or less.

7. (Currently Amended) ~~Use of a glycosaminoglycan~~ The method according to claim 2, ~~having,~~ wherein the at least one glycosaminoglycan has a sulfate/hexosamine ratio below 1.0 and an anticoagulant activity of 10 BP units/mg or less.

8. (Currently Amended) ~~Use of a glycosaminoglycan according to claim 1~~ The method according to claim 1, wherein the at least one glycosaminoglycan is administered in combination with oxytocin.

9. (Currently Amended) ~~Use of a glycosaminoglycans according to claim 1 for the manufacture of~~ The method according to claim 1, wherein the at least one glycosaminoglycan is administered topically in a topical pharmaceutical preparation.

10. (Currently Amended) ~~Use of a glycosaminoglycans according to claim 1 for the manufacture of~~ The method according to claim 1, wherein the at least one glycosaminoglycan is administered in a parenteral pharmaceutical preparation.

11. (New) The method according to claim 5, wherein the at least one glycosaminoglycan comprises depolymerised heparin having a molecular weight not higher than 6,000 Da.